Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients

By
Justin.choi
-
0
21
Rhizen Pharmaceuticals AG announced that it has commenced dosing in a Phase II trial to evaluate Tenalisib in patients with locally advanced or metastatic breast cancer.
[Rhizen Pharmaceuticals (BusinessNewsWire, Inc.)]

Sorry, but the selected Zotpress account can't be found.

Press Release